We are live on ! Find out more
LOAMS

Lombard Odier Asset Management (Switzerland) Portfolio holdings

AUM $2.63B
1-Year Est. Return 31.52%
This Fund
S&P 500
This Quarter Est. Return
+5.43%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.57B
AUM Growth
-$44M
Cap. Flow
-$44.8M
Cap. Flow %
-2.86%
Top 10 Hldgs %
22.89%
Holding
416
New
226
Increased
51
Reduced
95
Closed
41

Top Buys

Rank Stock Value
1
CIXX
CI Financial Corp.
CIXX
+$18.8M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$15.5M
3
VRTS icon
Virtus Investment Partners
VRTS
+$12.4M
4
AMZN icon
Amazon
AMZN
+$12.1M
5
MED icon
Medifast
MED
+$11.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$28.8M
2
VOYA icon
Voya Financial
VOYA
+$24.9M
3
ELS icon
Equity Lifestyle Properties
ELS
+$23.4M
4
BNTX icon
BioNTech
BNTX
+$16.1M
5
INDA icon
iShares MSCI India ETF
INDA
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 52.77%
2 Consumer Discretionary 15.05%
3 Financials 13.41%
4 Technology 7.21%
5 Industrials 3.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$24.1M 1.54%
175,176
-27,835
-14% -$3.54M
TXG icon
27
10x Genomics
TXG
$7.52B
$23.2M 1.48%
155,952
+13,180
+9% +$2.02M
NBIX icon
28
Neurocrine Biosciences
NBIX
$15.9B
$22.4M 1.43%
262,665
+22,682
+9% +$2.09M
NTRA icon
29
Natera
NTRA
$45.5B
$21.8M 1.39%
233,117
+19,717
+9% +$2.05M
AAPL icon
30
Apple
AAPL
$4.41T
$21.5M 1.37%
121,190
-29,401
-20% -$4.65M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$20M 1.28%
423,676
+216,930
+105% +$8.54M
IRTC icon
32
iRhythm Holdings
IRTC
$4.13B
$19M 1.21%
161,343
+61,571
+62% +$5.65M
TDOC icon
33
Teladoc Health
TDOC
$1.22B
$18.8M 1.2%
204,539
+17,264
+9% +$2.06M
IOVA icon
34
Iovance Biotherapeutics
IOVA
$3.05B
$18.1M 1.16%
949,884
+80,344
+9% +$1.77M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$17.9M 1.14%
121,736
+28,579
+31% +$4.44M
MSFT icon
36
Microsoft
MSFT
$3.66T
$17.3M 1.11%
51,555
-10,623
-17% -$3.44M
FATE icon
37
Fate Therapeutics
FATE
$317M
$15.9M 1.02%
272,011
+145,101
+114% +$8.22M
TWST icon
38
Twist Bioscience
TWST
$7.85B
$15.5M 0.99%
200,158
-16,726
-8% -$1.72M
ALLO icon
39
Allogene Therapeutics
ALLO
$714M
$14.9M 0.95%
996,116
+81,700
+9% +$1.44M
RCM
40
DELISTED
R1 RCM Inc. Common Stock
RCM
$14.7M 0.94%
577,798
+48,872
+9% +$1.17M
MDRX
41
DELISTED
Veradigm Inc. Common Stock
MDRX
$14.6M 0.93%
791,161
-349,314
-31% -$5.55M
POOL icon
42
Pool Corp
POOL
$7.25B
$14.2M 0.91%
25,167
-5,607
-18% -$2.94M
EXAS
43
DELISTED
Exact Sciences
EXAS
$13.9M 0.89%
178,148
-113,153
-39% -$9.99M
CRSP icon
44
CRISPR Therapeutics
CRSP
$5.22B
$13.5M 0.86%
+177,769
New +$15.5M
NTLA icon
45
Intellia Therapeutics
NTLA
$1.69B
$13.4M 0.86%
113,311
-35,495
-24% -$4.45M
NVTA
46
DELISTED
Invitae Corporation
NVTA
$12.1M 0.77%
790,396
+66,854
+9% +$1.45M
INMD icon
47
InMode
INMD
$875M
$12M 0.77%
170,000
-30,000
-15% -$2.41M
VRTS icon
48
Virtus Investment Partners
VRTS
$1.12B
$11.9M 0.76%
+40,000
New +$12.4M
AMZN icon
49
Amazon
AMZN
$2.88T
$11.8M 0.75%
+70,500
New +$12.1M
SGMO
50
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.6M 0.74%
1,539,994
+130,258
+9% +$1.13M
1
2
3 4 5

Similar funds

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
CCM
Cerberus Capital Management New York $2.65B AUM 20.18% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
MAMU
Marathon Asset Management (UK) London, United Kingdom $2.61B AUM 27.14% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s Q4 2021 Portfolio in Review

As of Q4 2021, Lombard Odier Asset Management (Switzerland) held 416 positions worth $1.57B, down 2.7% from $1.61B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Lombard Odier Asset Management (Switzerland)'s Q4 2021 filing shows 226 new, 51 increased, 95 reduced and 41 closed positions. Its largest new stake was CRISPR Therapeutics: 177,769 shares worth $13.5M. The largest sale was Merck, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Lombard Odier Asset Management (Switzerland)'s largest Q4 2021 buy was CRISPR Therapeutics: 177,769 shares worth $13.5M.
  • Lombard Odier Asset Management (Switzerland) added most to CI Financial Corp. in Q4 2021, an estimated $18.8M increase.
  • Lombard Odier Asset Management (Switzerland)'s biggest Q4 2021 reduction was Merck, cutting an estimated $28.8M.
  • Lombard Odier Asset Management (Switzerland) fully exited Voya Financial in Q4 2021, selling an estimated $24.9M.
  • Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 23% of its $1.57B portfolio in Q4 2021.
  • Lombard Odier Asset Management (Switzerland) opened 226 new positions and closed 41 in Q4 2021.
  • Lombard Odier Asset Management (Switzerland)'s portfolio value fell 2.7% quarter-over-quarter to $1.57B.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q4 2021, filed 14 Feb 2022.